nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.05.2010 | Epidemiology

Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis

verfasst von: Ni Li, Jing Dong, Zhibin Hu, Hongbing Shen, Min Dai

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Estrogen exposure is a central risk factor in the development of breast cancer. Estrogen receptor alpha (coded by ESR1) is the key mediator of estrogen response in mammary tissue. Genetic changes altering the expression of ESR1 is likely to affect breast cancer susceptibility. Since the identification of several potentially functional polymorphisms in ESR1 (rs2234693, rs9340799, rs1801132, rs3798577, rs2228480), molecular epidemiological studies were conducted in recent years to evaluate the association between polymorphisms and breast cancer risk in diverse populations. However, the results remain conflicting rather than conclusive. This current analysis on 10,300 breast cancer cases and 16,620 controls on rs2234693 showed a borderline significant decreased breast cancer risk for CC and CC/CT carriers (CC vs. TT: OR, 0.92, 95% CI, 0.86–0.99; CC/CT vs. TT: OR, 0.95, 95% CI, 0.89–1.00). Variant genotypes of the rs1801132 polymorphism were also associated with a decreased breast cancer risk in a dominant model in 5,649 cases and 6,856 controls (GG/GC vs. CC: OR, 0.92, 95% CI, 0.85–0.99). These results suggest that potentially functional ESR1 polymorphisms may play a low penetrance role in breast cancer susceptibility. SNPs rs9340799, rs3798577, rs2228480, and rs2077647 in ESR1 were not causative SNPs. SNPs rs2747648, rs1062577, and rs3020314 were recommended in further association studies and functional evaluations.

Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous hormones and breast cancer collaborative group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616PubMed

Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90(1):37–42CrossRefPubMed

Zuppan P, Hall JM, Lee MK, Ponglikitmongkol M, King MC (1991) Possible linkage of the estrogen receptor gene to breast cancer in a family with late-onset disease. Am J Hum Genet 48(6):1065–1068PubMed

Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL, Gu K, Fair AM, Cai Q, Lu W, Shu XO (2009) Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009 Mar; 41(3):324–328. Epub 2009 Feb 15

Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR, Gao YT, Zheng W (2003) Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai breast cancer study. Cancer Epidemiol Biomarkers Prev 12(9):853–859PubMed

Dunning AM, Healey CS, Baynes C, Maia AT, Scollen S, Vega A, Rodríguez R, Barbosa-Morais NL, Ponder BA; SEARCH, Low YL, Bingham S; EPIC, Haiman CA, Le Marchand L; MEC, Broeks A, Schmidt MK; ABCS, Hopper J, Southey M; ABCFS, Beckmann MW, Fasching PA; BBCC, Peto J, Johnson N; BBCS, Bojesen SE, Nordestgaard B; CGPS, Milne RL, Benitez J; CNIO-BCS, Hamann U, Ko Y; GENICA, Schmutzler RK, Burwinkel B; GC-HBOC, Schürmann P, Dörk T; HABCS, Heikkinen T, Nevanlinna H; HEBCS, Lindblom A, Margolin S; KARBAC, Mannermaa A, Kosma VM; KBCS, Chen X, Spurdle A; kConFab and the AOCS Management Group, Change-Claude J, Flesch-Janys D; MARIE, Couch FJ, Olson JE; for MCBCS, Severi G, Baglietto L; MCCS, Børresen-Dale AL, Kristensen V; NBCS, Hunter DJ, Hankinson SE; NHS, Devilee P, Vreeswijk M; ORIGO, Lissowska J, Brinton L; PBCS, Liu J, Hall P; SASBAC, Kang D, Yoo KY; SEBCS, Shen CY, Yu JC; TWBCS, Anton-Culver H, Ziogoas A; UCIBCS, Sigurdson A, Struewing J; USRTS, Easton DF, Garcia-Closas M, Humphreys MK, Morrison J, Pharoah PD, Pooley KA, Chenevix-Trench G, BCAC (2009) Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 2009 Mar 15; 18(6):1131–1139. Epub 2009 Jan 6

González-Mancha R, Galán JJ, Crespo C, Pérez LI, González-Perez A, Morón FJ, Nogueira JAM, Real LM, Pascual MH, Ruiz A, Royo JL (2008) Analysis of the ERalpha germline PvuII marker in breast cancer risk. Med Sci Monit 14(3):CR136–CR143PubMed

González-Zuloeta Ladd AM, Vásquez AA, Rivadeneira F, Siemes C, Hofman A, Stricker BH, Pols HA, Uitterlinden AG, van Duijn CM (2008) Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk. Breast Cancer Res Treat 2008 Feb; 107(3):415–419. Epub 2007 Apr 24

Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, Axelsson CK, Grønholdt ML, Grande P, Jensen GB, Nordestgaard BG (2007) Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case–control studies and a meta-analysis. Circulation 115(7):861–871CrossRefPubMed

10.

Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH (2005) The estrogen receptor alpha gene and breast cancer risk (The Netherlands). Cancer Causes Control 16(10):1195–1202CrossRefPubMed

11.

Shen Y, Li DK, Wu J, Zhang Z, Gao E (2006) Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case–control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 15(2):342–347CrossRefPubMed

12.

Shin A, Kang D, Nishio H, Lee MJ, Park SK, Kim SU, Noh DY, Choe KJ, Ahn SH, Hirvonen A, Kim JH, Yoo KY (2003) Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 80(1):127–131CrossRefPubMed

13.

Sonestedt E, Ivarsson MI, Harlid S, Ericson U, Gullberg B, Carlson J, Olsson H, Adlercreutz H, Wirfält E (2009) The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes. J Nutr 2009 May;139(5):993–1001. Epub 2009 Mar 25

14.

Wang J, Higuchi R, Modugno F, Li J, Umblas N, Lee J, Lui LY, Ziv E, Tice JA, Cummings SR, Rhees B (2007) Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat 2007 Dec;106(2):273–280. Epub 2007 Feb 1

15.

Wedrén S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvänen AC, Kindmark A, Landegren U, Fermér ML, Stiger F, Persson I, Baron J, Weiderpass E (2004) Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 2004;6(4):R437–R449. Epub 2004 Jun 4

16.

Comings DE, Gade-Andavolu R, Cone LA, Muhleman D, MacMurray JP (2003) A multigene test for the risk of sporadic breast carcinoma. Cancer 97(9):2160–2170CrossRefPubMed

17.

Slattery ML, Curtin K, Giuliano AR, Sweeney C, Baumgartner R, Edwards S, Wolff RK, Baumgartner KB, Byers T (2007) Active and passive smoking, IL6, ESR1, and breast cancer risk. Breast Cancer Res Treat 2008 May;109(1):101–111. Epub 2007 Jun 27

18.

Fernández LP, Milne RL, Barroso E, Cuadros M, Arias JI, Ruibal A, Benítez J, Ribas G (2006) Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case–control study. Int J Cancer 119(2):467–471CrossRefPubMed

19.

Gallicchio L, Berndt SI, McSorley MA, Newschaffer CJ, Thuita LW, Argani P, Hoffman SC, Helzlsouer KJ (2006) Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. BMC Cancer 6:173CrossRefPubMed

20.

Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang H, Chen M, Lippert R, Halldorsson BV, Woodworth B, White T, Clark AG, Parl FF, Broder S, Dean M, Offit K (2004) Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res 64(24):8891–8900CrossRefPubMed

21.

Siddig A, Mohamed AO, Awad S, Hassan AH, Zilahi E, Al-Haj M, Bernsen R, Adem A (2008) Estrogen receptor alpha gene polymorphism and breast cancer. Ann N Y Acad Sci 1138:95–107CrossRefPubMed

22.

Weiderpass E, Persson I, Melhus H, Wedrén S, Kindmark A, Baron JA (2000) Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis 21(4):623–627CrossRefPubMed

23.

Georgiou I, Syrrou M, Bouba I, Dalkalitsis N, Paschopoulos M, Navrozoglou I, Lolis D (1999) Association of estrogen receptor gene polymorphisms with endometriosis. Fertil Steril 72(1):164–166CrossRefPubMed

24.

Weel AE, Uitterlinden AG, Westendorp IC, Burger H, Schuit SC, Hofman A, Helmerhorst TJ, van Leeuwen JP, Pols HA (1999) Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab 84(9):3146–3150CrossRefPubMed

25.

Stavrou I, Zois C, Ioannidis JP, Tsatsoulis A (2002) Association of polymorphisms of the oestrogen receptor alpha gene with the age of menarche. Hum Reprod 17(4):1101–1105CrossRefPubMed

26.

Gennari L, Becherini L, Masi L, Mansani R, Gonnelli S, Cepollaro C, Martini S, Montagnani A, Lentini G, Becorpi AM, Brandi ML (1998) Vitamin D and estrogen receptor allelic variants in Italian postmenopausal women: evidence of multiple gene contribution to bone mineral density. J Clin Endocrinol Metab 83(3):939–944CrossRefPubMed

27.

Willing M, Sowers M, Aron D, Clark MK, Burns T, Bunten C, Crutchfield M, D’Agostino D, Jannausch M (1998) Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction. J Bone Miner Res 13(4):695–705CrossRefPubMed

28.

Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER (2003) Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002 Apr 23;105(16):1879–1882. Erratum in: Circulation. 2003 Jul 29; 108(4):5001

29.

Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A, Pols HA, Uitterlinden AG (2004) Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 291(24):2969–2977CrossRefPubMed

30.

Ioannidis JP, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, Langdahl B, van Meurs JB, Mosekilde L, Scollen S, Albagha OM, Bustamante M, Carey AH, Dunning AM, Enjuanes A, van Leeuwen JP, Mavilia C, Masi L, McGuigan FE, Nogues X, Pols HA, Reid DM, Schuit SC, Sherlock RE, Uitterlinden AG, GENOMOS Study (2004) Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 292(17):2105–2114CrossRefPubMed

31.

Tchatchou S, Jung A, Hemminki K, Sutter C, Wappenschmidt B, Bugert P, Weber BH, Niederacher D, Arnold N, Varon-Mateeva R, Ditsch N, Meindl A, Schmutzler RK, Bartram CR, Burwinkel B (2009) A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis 2009 Jan; 30(1):59–64. Epub 2008 Nov 20

32.

Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR, Stone KL, Morin PA, Greene D, Cauley JA (2005) Estrogen metabolizing polymorphisms and breast cancer risk among older white women. Breast Cancer Res Treat 93(3):261–270CrossRefPubMed

33.

Einarsdóttir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, Sjölander A, Czene K, Wedrén S, Liu ET, Hall P, Humphreys K, Liu J (2008) ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 2008; 10(1):R15. Epub 2008 Feb 14

34.

Petitti DB (1994) Meta-analysis, decision analysis, and cost-effectiveness analysis. Oxford University Press, New York

35.

Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826PubMed

36.

Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed

37.

Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K (2008) Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008 May 29; 358(22):2355–2365. Epub 2008 Apr 29

38.

Herynk MH, Fuqua SA (2004) Estrogen receptor mutations in human disease. Endocr Rev 25(6):869–898CrossRefPubMed

39.

Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM (2007) Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 67(20):9609–9612CrossRefPubMed

40.

Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O’Malley BW, McGuire WL (1991) Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51(1):105–109PubMed

Titel: Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis
verfasst von: Ni Li
Jing Dong
Zhibin Hu
Hongbing Shen
Min Dai
Publikationsdatum: 01.05.2010
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0532-9

Springer Medizin

Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort

Are PALB2 mutations associated with increased risk of male breast cancer?

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines

Some common mutations of RAD50 and NBS1 in western populations do not contribute significantly to Chinese non-BRCA1/2 hereditary breast cancer

Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer

Sensitivity analyses including and excluding the HWE-violating studies are required for meta-analyses of genetic association studies

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie